Methods for Engineering Binders to Multi-Pass Membrane Proteins

Author:

Thomas Benjamin1,Chockalingam Karuppiah2,Chen Zhilei12ORCID

Affiliation:

1. Interdisciplinary Graduate Program in Genetics and Genomics, Texas A&M University, College Station, TX 77845, USA

2. Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, TX 77807, USA

Abstract

Numerous potential drug targets, including G-protein-coupled receptors and ion channel proteins, reside on the cell surface as multi-pass membrane proteins. Unfortunately, despite advances in engineering technologies, engineering biologics against multi-pass membrane proteins remains a formidable task. In this review, we focus on the different methods used to prepare/present multi-pass transmembrane proteins for engineering target-specific biologics such as antibodies, nanobodies and synthetic scaffold proteins. The engineered biologics exhibit high specificity and affinity, and have broad applications as therapeutics, probes for cell staining and chaperones for promoting protein crystallization. We primarily cover publications on this topic from the past 10 years, with a focus on the different formats of multi-pass transmembrane proteins. Finally, the remaining challenges facing this field and new technologies developed to overcome a number of obstacles are discussed.

Funder

NIH

Publisher

MDPI AG

Subject

Bioengineering

Reference90 articles.

1. Zhao, H., Dodds, M., Tasch, M., Gewe, M., Martinez, A., Hutton, M., Keeney, K., Pollock, A., Jester, B.W., and Khuong, N. (2022). Using synthetic activity to design ultra-potent antibody cocktails. bioRxiv.

2. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin;Mankarious;J. Lab. Clin. Med.,1988

3. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants;Griffin;N. Engl. J. Med.,2020

4. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease;Luytjes;Front. Immunol.,2019

5. Boosting therapeutic potency of antibodies by taming Fc domain functions;Kang;Exp. Mol. Med.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3